lung cancer
Conditions
Interventions
Adjuvant treatment of S-1 is administered on alternate-day for 1 year after surgery.
Sponsors
Chiba University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. histologically proven non-small cell lung cancer with stage IB to IIIA 2. curative resection (R0) at the prior surgery 3.without any prior radiation therapy, chemotherapy for primary lung cancer. 4. age: 20< years old 5. PS(ECOG): 0 or 1 6. without any other severe diseases WBC 3,000<= and => 12,000/mm3 Platelet 100,000/mm3 <= Hemoglobin 9.0 g.dl <= Total bilirubin 1.5 mg/dl => AST, ALT 100 IU/L <= SPO2 90% <= or PaO2 60mmHg <= Creatinin clearance 40 ml/min/body <= **Cockcroft-Gault method is available 7.patients who can start adjuvant treatment within 8 weeks postoperatively. 8. written informed consents
Exclusion criteria
Exclusion criteria: 1) patients who cannot take S-1 1.with severe allergic history against the ingredients of S-1. 2. with sever bone marrow suppression, renal or liver dysfunction 3. patients who need other fluorouracil 4. patients who need flucitosine. 2) with severe allergic history against medicines 3) with history of myocardial infarction in 6 months. 4)with other severe diseases (cardiac failure,mental disorder, infection or other severe complications) 5) with uncontrolled DM 6) with watery diarrhea 7) with double cancer and or multiple cancer 8)doctors' stop not to register to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ratio of the patients who completed the course | — |
Countries
Japan
Contacts
Public ContactHidemi Suzuki
Chiba University Graduate School of Medicine Department of General Thoracic Surgery
Outcome results
None listed